Effects of arginine vasotocin on REM sleep in narcoleptics and in symptomatic hypersomniacs.
Arginine vasotocin (AVT), in doses of 1.5 microgram, administered intranasally to two narcoleptics (a male aged 42 years and a female aged 35 years), as well as to 5 symptomatic hypersomniacs (3 females and 2 males), aged 25-57 years, induced very rapidly in most instances in sleep with REM periods at onset and markedly increased in amount of REM sleep during a fixed period of 180 min of sleep recording. After AVT administration there was a significant shortening of the time of occurrence of the first REM sleep period both in narcoleptics (t test = 0.05 greater than P greater than 0.025) and in symptomatic hypersomniacs (t test = 0.02 greater than P greater than 0.01).
D000328:Adult; D006970:Disorders of Excessive Somnolence / Q000188:drug therapy*; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009290:Narcolepsy / Q000188:drug therapy*; D012894:Sleep Stages / Q000187:drug effects; D012893:Sleep Wake Disorders / Q000188:drug therapy*; D012895:Sleep, REM / Q000187:drug effects*; D014668:Vasotocin / Q000627:therapeutic use*
D014668:Vasotocin